Literature DB >> 2150190

Renal effects of the new calcium channel blocking drug isradipine.

B K Krämer1, M Häussler, K M Ress, G A Müller, K J Burger, T Risler.   

Abstract

The acute effect of a single oral dose of isradipine 5 mg on blood pressure, renal haemodynamics, electrolyte excretion and plasma renin activity was studied in 10 healthy males. Isradipine did not produce a significant change in systolic or diastolic blood pressure, and glomerular filtration rate, renal plasma flow, renal vascular resistance, and urinary albumin excretion remained constant. There was a marked natriuretic and diuretic effect about 1-3 h after isradipine. Plasma renin activity showed a slight, insignificant increase 1 h after dosing. Uric acid clearance and beta 2-microglobulin excretion showed no significant changes, despite an increase in sodium clearance, suggesting an additional mechanism of action other than the proximal tubular natriuretic effect of isradipine in normotensive volunteers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150190     DOI: 10.1007/bf00315405

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Comparison of isradipine and nifedipine in chronic stable angina.

Authors:  C E Handler; E Rosenthal; D Tsagadopoulos; Y Najm
Journal:  Int J Cardiol       Date:  1988-01       Impact factor: 4.164

2.  Comparison of acute effects of nifedipine in normotensive and hypertensive man.

Authors:  O Lederballe Pedersen; N J Christensen; K D Rämsch
Journal:  J Cardiovasc Pharmacol       Date:  1980 Jul-Aug       Impact factor: 3.105

3.  Acute natriuretic effect of nifedipine in hypertensive patients and normotensive controls--a proximal tubular effect?

Authors:  L R Krusell; C K Christensen; O Lederballe Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  Short- and long-term effects of calcium entry blockers on the kidney.

Authors:  J H Bauer; G Reams
Journal:  Am J Cardiol       Date:  1987-01-23       Impact factor: 2.778

5.  Evaluation of isradipine (PN 200-110) in mild to moderate hypertension.

Authors:  N Winer; S Thys-Jacobs; R Kumar; W D Davidson; M Grayson; C Harris; D Walker; H Itskovitz; L Gonasun
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

6.  Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man.

Authors:  F L Tse; J M Jaffe
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Cardiovascular and renal effects of single administration of three different doses of isradipine in hypertensive patients. Dose-response curves of the different effects.

Authors:  L Rupoli; M Fruscio; R Gradnik; R Chianca; G Leonetti; A Zanchetti
Journal:  Am J Med       Date:  1989-04-17       Impact factor: 4.965

8.  Long-term effects of isradipine on blood pressure and renal function.

Authors:  O L Pedersen; L R Krusell; I Sihm; L T Jespersen; K Thomsen
Journal:  Am J Med       Date:  1989-04-17       Impact factor: 4.965

9.  Renal and hemodynamic effects of isradipine in essential hypertension.

Authors:  B Persson; O K Andersson; M Wysocki; T Hedner; M Aurell
Journal:  Am J Med       Date:  1989-04-17       Impact factor: 4.965

10.  Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist.

Authors:  E B Nelson; J L Pool; A A Taylor
Journal:  Clin Pharmacol Ther       Date:  1986-12       Impact factor: 6.875

View more
  2 in total

Review 1.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

Review 2.  Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.